NCT06568172 2026-04-16
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Children's Oncology Group
National Cancer Institute (NCI)